Melanoma Genel Bakış

Abstract

Kutanöz melanom özellikle artan UV maruziyeti nedeniyle insidansı tüm dünyada artış gösteren bir malignitedir. Tüm deri kanserlerinin yalnızca %4’ünü oluşturmasına rağmen deri kanserleri ile ilişkili ölümlerin başlıca nedeni olarak karşımıza çıkmaktadır. Hastalık ilerledikçe hem prognozu kötüleşmekte hem de tedavi maliyeti artmaktadır. Erken evrede saptanabilen melanomlarda lokal eksizyon ile %90’ın üzerinde tedavi sağlanabilirken ileri evre melanomlarda 5 yıllık sağ kalım oranı cerrahi ve kemoterapi uygulamasına rağmen ancak %20 civarındadır. planlanması ve prognozlarının tayininde önemlidir. Bugüne kadar evrelemesi

Keywords

• Melanoma, Tanı, Evreleme, Tedavi

-

Abstract

ABTRACT Cutaneous melanoma is a malignancy which has an increasing incidence in all over the world especially due to increased UV exposure. Although it builds only 4% of all skin cancers, it is the major cause of death appears to be associated with skin cancer. As the disease progresses both cost of the treatment and worsening of the prognosis increases. Local excision of melanomas detected at an early stage may provide over 90% cure on the other hand despite surgery and chemotherapy 5-year survival rate of treatment of advanced-stage melanomas is about 20%. Melanoma staging is important in determining treatment planning and prognosis of patients. Different systems have been developed for staging melanoma to date but most of them considered inadequate. In parallel with developments in science, innovations in imaging and genetic studies brought a number of changes in the treatment and staging of melanoma. Some drugs which has been tried in the early nineties, now taken its place today as part of the treatment. Prognostic factors and treatment regimens considered to be effective on survival have uncovered with a number of studies. In this article it is intended to increase awareness of health care workers about cutaneous melanoma. In addition, the current staging system for melanoma, treatment modalities and factors thought to be effect on prognosis will be mentioned

Keywords

• -

References

1. Giblin AV, Thomas JM. Incidence, mortality and survival in cutaneous melanoma. Journal of Plastic Surgery 2007; 60(1):32-40.
2. Özgün E, Seckin S, Ergocen S. İntradermal Melanositik Nevüs, Displastik Nevüs ve Malign Melanomanın Ayırıcı Tanısında Ki-67’nin Önemi ve Ki-67’nin Malign Melanomada Prognostik Faktörlerle Karşılaştırılması. Turkiye Klinikleri J Dermatol 2009;19(4):184-92.
3. Ko JM, Velez NF and Tsao H. Pathways to Melanoma. Semin Cutan Med Surg 2010;29(4):210-7.
4. Tucker MA, Halpern A, Holly EA, et al: Clinically recognized dysplastic nevi. A central risk factor for cutaneous melanoma. JAMA 1997;277(18):1439-44.
5. Wang SQ, Setlow R, Berwick M, et al. Ultraviolet A and melanoma: a review. J Am Acad Dermatol 2001;44(5):837-46. Parlak A ve ark.
6. Goldstein BG, Goldstein OA. Diagnosis and Management of Malignant Melanoma. Am Fam Physician 2001;63 (7):1359-68.
7. MacKie RM. Incidence, risk factors and prevention of melanoma. Eur J Cancer 1998;34(3):3-6.
8. Braun-Falco O, Burgdorf WHC, Plewing G, et al. Braun-Falco Dermatology. 3rd ed. Italy: Springer; 2009:1416-32.

9. Savage LM, Boehmer L, McBride A. Melanoma: review of pathogenesis and treatment options. US Pharm. 2010;35(9)(Oncology suppl):8-16.
10. Wolf K, Goldsmith LA, Katz SI, et al. Fitzpatrick’s Dermatology in General Medicine. 7th ed. USA: Mc Graw Hill Companies; 2008:1134-57.
11. Gökdemir A, Özden MG, Bek Y, et al. Melanositik ve non-melanositik lezyonlarda dermoskopik ve histopatolojik tanı korelasyonu. Turkiye Klinikleri J Dermatol 2011;21(1):7-16.
12. Balch CM, Soong SJ, Atkins MB, et al. An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin 2004;54(3):131-49.
13. Piris A, Mihm MC, Duncan LM. AJCC melanoma staging update: impact on dermatopathology practice and patient management. J Cutan Pathol 2011;38(5):394-400.
14. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001;19(16):3622-34.
15. Payette MJ, Katz M, Grant-Kels JM. Melanoma prognostic factors found in the dermatopathology report. Clinics in Dermatology 2009;27(1):53–74.
16. Massi D, Franchi A, Borgognoni L, et al. Thin cutaneous malignant melanomas (< or =1.5 mm): identification of risk factors indicative of progression. Cancer 1999;85(5):1067-76.
17. Tüzün Y, Gürer MA, Serdaroğlu S, et al. Dermatoloji. 3. Baskı. İstanbul: Nobel Tıp Kitabevleri; 2008:791- 1820.
18. Eggermont AMM, Testori A, Marsden J, et al. Utility of adjuvant systemic therapy in melanoma. Ann Oncol 2009;20(6):30-4.
19. Gogas HJ, Kirkwood JM, Sondak VK. Chemotherapy for metastatic melanoma: time for a change? Cancer 2007;109(3):455-64.
20. Eggermont AM, Kirkwood JM. Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? Eur J Cancer 2004;40(12):1825-36.
21. Agarwala SS, Kirkwood JM, Gore M, et al. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J Clin Oncol 2004;22(11):2101-7.
22. Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000;18(1):158-66.
23. Atkins MB. The treatment of metastatic melanoma with chemotherapy and biologics. Curr Opin Oncol 1997;9(2):205-13.
24. Fletcher WS, Green S, Fletcher JR, et al. Evaluation of cis-platinum and DTIC combination chemotherapy in disseminated melanoma. A southwest oncology group study. Am J Clin Oncol 1988;11(5):589-93.
25. Vorobiof DA, Sarli R, Falkson G. Combination chemotherapy with dacarbazine and vindesine in the treatment of metastatic malignant melanoma. Cancer Treat Rep 1986;70(7):927-8.
26. Legha SS, Ring S, Bedikian A, et al. Papadopoulos N. Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha. Ann Oncol 1996;7(8):827-35.
27. Legha SS, Ring S, Eton O, et al. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alpha and interleukin-2 for patients with metastatic melanoma. J Clin Oncol 1998;16(5):1752-9.
28. Atkins MB, O'Boyle KR, Sosman JA, et al. Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma. J Clin Oncol 1994;12(8):1553-60.
29. Kirkwood JM, Moschos S, Wang W. Strategies for the development of more effective adjuvant therapy of melanoma: current and future explorations of antibodies, cytokines, vaccines, and combinations. Clin Cancer Res 2006;12(7):2331-6.
30. Weber J. Overcoming immunological tolerance to melanoma: targeting CTLA-4 with ipilimumab (MDX- 010). Oncologist 2008;13(4):16-25.
31. Beck KE, Blansfield JA, Tran KQ, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 2006;24(15):2283-9.
32. Ribas A, Camacho LH, Lopez-Berestein G, et al. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP- 675,206. J Clin Oncol 2005;23(35):8968-77.